Company ProfilePremium

Grand Brilliance Group Holdings Limited

Company Profile Analysis

君百延集團控股有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Grand Brilliance Group Holdings Limited - Company showcase

Year Founded & Workforce

1997

51 Employees

Grand Brilliance Group Holdings Limited logo

Grand Brilliance Group Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Grand Brilliance Group Holdings Limited Overview

Grand Brilliance Group is a founder-controlled Hong Kong medical device distributor and "one-stop medical device solutions provider" with more than two decades of local market experience. It sources devices, consumables and instruments from roughly fifty overseas and regional manufacturers — principally in Mainland China, the United States, Germany and France — and sells them to Hong Kong hospitals, clinics and other healthcare buyers, wrapping the products with procurement advice, installation, after-sales maintenance, technical training, rental and quality-assurance services. Revenue crossed HK$100 million for the first time in FY2026 (HK$100.7 million), driven by tender wins for equipment supply to existing-hospital expansions under the HKSAR Government's First Hospital Development Plan. The company is debt-free, holds HK$53 million of cash against a market capitalisation of about HK$135 million, and is attempting to build an own-brand autonomous mobile robot (AMR) and medical-device capability to address Hong Kong's healthcare manpower shortage. Scale is very small, customer concentration is rising, and receivables quality deteriorated sharply at FY2026 year end.


The company's own description (latest annual results, FY2026)

In its FY2026 results announcement (26 June 2026), the company describes itself as an established medical device distributor and one-stop medical device solutions provider with over 20 years of experience in the Hong Kong medical device market. Its principal activities are described as the supply of medical devices and the provision of medical device solutions, comprising market trend analysis, medical device sourcing, after-sales services, technical support and training services, medical device rental services and quality assurance (Note 1 and Note 4, FY2026 results). Management states that during FY2026 it continued to implement strategies to consolidate its position as a major medical device distributor in Hong Kong, that it has established a subsidiary to facilitate future development of own-brand medical devices, and that growth was achieved through a diversified product portfolio and enhanced R&D capability.

Business model and revenue model

Revenue model componentDescriptionFY2026 revenue (HKD K)Share of FY2026 revenue (%)
Product sales — medical consumablesSingle-use and recurring-purchase consumables; recognised at a point in time on delivery and acceptance61,90261.5
Product sales — medical equipmentCapital equipment, frequently via public tenders; where installation is required, revenue is recognised on customer acceptance after installation34,24834.0
Product sales — medical instrumentsReusable instruments1,5401.5
Services — maintenanceMaintenance service contracts recognised over time2,8672.8
Rental — medical device leasingOperating-lease rental income on medical devices1560.2
Total—100,713100.0

The business is overwhelmingly a product-resale model with a thin but growing service layer:

Source: FY2026 results announcement, Note 5. Percentages analyst-derived.

There is no subscription or licensing revenue. Recurring revenue is best approximated by consumables (repeat purchasing by installed hospital/clinic accounts) plus maintenance contracts — together about 64% of FY2026 revenue. Equipment revenue is lumpier and tender-driven.

Value-chain position

The FY2023 ESG report describes the group as a bridge between overseas medical device suppliers and customers, managing pre-sale and post-sale matters, relaying product updates from manufacturers to users and channelling user feedback back to manufacturers. The value chain is: manufacturer → Grand Brilliance (registration, import, warehousing, QC inspection, sales, installation, maintenance, recall management) → hospitals, clinics and others. Quality controls disclosed include sourcing only from approved suppliers, inbound QC inspection of all products, sterilisation certificates for single-use devices, a product traceability/labelling system supporting recalls, a typical one-year product warranty to customers, and product liability insurance (FY2023 ESG report, B6).

Customer types and end-markets

Public hospitals and public-sector tenders: FY2025 and FY2026 revenue growth was explicitly attributed to winning tenders to supply medical equipment for expansions of existing hospitals under the HKSAR Government's First Hospital Development Plan (FY2025 and FY2026 results MD&A). The group also provides bank-issued performance bonds for certain tender contracts (HK$1.154 million outstanding at 31 March 2026).

Private hospitals and clinics: Not separately quantified.

Retail customers: The company redesigned its website to add an e-commerce platform for retail customers (FY2024 results, business-progress table).

Concentration: Two customers each exceeded 10% of revenue in FY2026: Customer A HK$15.689 million (15.6%) and Customer B HK$10.340 million (10.3%); in FY2025 Customer A contributed HK$18.608 million (19.7%) and Customer B HK$9.743 million (10.3%). In FY2023, no customer exceeded 10%; the top five customers contributed 32.9% and the largest 7.3% (FY2023 AR). Customer identities are not disclosed.

Independent characterisation

Grand Brilliance is a micro-cap, owner-managed distribution business whose economics resemble a specialist trading house: high gross margins for a distributor (46–52%) reflecting niche product agency rights and value-added services, but a heavy fixed cost base (administrative expenses equal to roughly 38% of revenue) that compresses operating margin to 6–10%. Growth since FY2024 has been driven by public-hospital capital equipment tenders, which carry lower margins than consumables (gross margin fell from 51.5% in FY2023 to 46.1% in FY2026, attributed by management to product-mix change). The "technology" angle — AMRs and own-brand devices — remains pre-revenue and has so far produced investment write-downs offset by a bargain-purchase accounting gain. The balance sheet is conservatively financed (no bank borrowings), but working-capital intensity is very high: inventory days of roughly 175–230 and, at FY2026 year end, receivables more than 90 days old of HK$29.5 million (69% of net trade receivables).

Strategy

Stated strategic themes (paraphrased from FY2025 and FY2026 MD&A and chairman's statements)

  1. Consolidate position as a major Hong Kong medical device distributor.

  2. Diversify the product portfolio to drive growth.

  3. Strengthen R&D capability, including establishing a subsidiary to develop own-brand medical devices.

  4. Enhance customer service to strengthen the one-stop solutions offering.

  5. Automation to address healthcare manpower shortages, chiefly via AMR solutions.

  6. Seek suitable investment opportunities to diversify the business and improve shareholder returns.

  7. Structural tailwinds cited: an ageing population and rising health awareness in Hong Kong.

Original IPO strategy vs. execution (FY2024 results, business-progress table)

Prospectus objectiveReported progress to 31 Mar 2024
Penetrate market and increase shareParticipation in Hospital Authority Convention, Hong Kong International Medical and Healthcare Fair, paediatric society scientific meetings; e-commerce website; showroom samples
Expand workforceRecruited 7 product representatives, 2 engineers, 1 warehouse staff, 2 R&D staff, 1 admin, 2 marketing, 1 accountant
Selectively pursue strategic acquisitions"Carefully identifying potential targets" — no acquisition of a revenue-generating business completed
Enhance R&D and product developmentRecruited two software engineers; researching healthcare automation solutions
Upgrade IT systemsImplemented ERP with an independent consultant
Expand warehouse, build showroom, upgrade officeShowroom built; warehouse racking installed

Initiatives in the last 24 months (Oct 2024 – Oct 2026)

InitiativeDateDetailStatus
Control of AMR JV6 Feb 2025Techmetics Sonne stake raised to 60% for US$100; aim to expand healthcare AMR footprint and develop group-branded AMR solutionsSubsidiary; no revenue contribution in FY2025 (loss HK$158,000 post-acquisition)
Own-brand device subsidiaryFY2025–FY2026Subsidiary established to drive future own-brand device developmentNo revenue disclosed
Public hospital tender programmeFY2025–FY2026Tender wins for equipment supply to existing hospital expansions under the First Hospital Development PlanMain growth driver
Macau expansionFY2024 onwardNon-wholly-owned subsidiaryRevenue undisclosed
R&D fundingFY2024–FY2026ITF Research Talent Hub (HK$241k FY2026), Cash Rebate Scheme for R&D investment (HK$394k FY2026), Enterprise Support Scheme (HK$21k FY2026)Declining grant income
Treasury share / buyback mandatesAGM 11 Sep 2026General mandates to issue new shares, sell/transfer treasury shares and repurchase sharesMandate only; no buyback executed in FY2026

Sustainability/ESG commitments

Targets set against an FY2022 baseline to maintain or reduce intensity through FY2030: GHG intensity (0.74 tCO2e per HK$ million revenue), non-hazardous waste intensity (11.86 kg per HK$ million), energy intensity (2,056.04 kWh per HK$ million), and total water consumption (FY2023 ESG report).

Cost programmes and medium-term financial targets

No cost-reduction programme with quantified targets, and no medium-term financial targets or guidance, have been published.

Products & Services

Disclosure limitation. The annual results announcements and the FY2023 Annual Report reviewed do not list individual product brands, models, agency agreements or prices. The catalogue below is organised at the most granular level the company discloses.

Medical consumables

Description: Recurring-use and single-use medical consumables supplied to hospitals and clinics. The company's QC procedures specifically reference single-use medical devices requiring supplier sterilisation certificates (FY2023 ESG report).

Target customers: Public and private hospitals, clinics; some retail sales via the e-commerce platform.

Pricing model: Per-unit product sales; credit terms of 0–30 days to customers (FY2026 results, Note 12).

Inventory: Consumables inventory was HK$16.340 million at 31 March 2023 (FY2023 AR, Note 21); later year splits not captured.

Named flagship offerings: Not publicly disclosed.

Medical equipment

Description: Capital medical equipment, including equipment requiring installation (revenue recognised upon customer acceptance post-installation).

Key driver: Tender wins for equipment supply to existing-hospital expansion projects under the First Hospital Development Plan (FY2025 and FY2026 MD&A).

Pricing model: Tender-based contract pricing; performance bonds provided via banks for certain tender contracts (HK$1.154 million at 31 March 2026, with most contracts expected to complete by FY2027).

Named flagship offerings: Not publicly disclosed.

Medical instruments

Description: Reusable medical instruments. Revenue has declined every year since FY2022 (HK$2.445 million in FY2022).

Named flagship offerings: Not publicly disclosed.

Maintenance and after-sales services

Description: Maintenance service contracts recognised over the contract period, delivered through dedicated subsidiary 鴻日工程服務有限公司. The group designates staff and engineers to inspect medical equipment regularly and maintains repair-process records (FY2023 ESG report).

Growth: +23.7% in FY2026, the fastest-growing line, consistent with a larger installed equipment base.

Medical device rental (FY2026 revenue HK$156,000; 0.2%)

Description: Operating leases of medical devices; flat at HK$156,000 per year since FY2023.

Solutions services (embedded in product revenue)

The company markets a bundled "one-stop solution" comprising: market trend analysis; medical device sourcing; after-sales services; technical support and training; rental; and quality assurance (FY2026 results, Note 1). These are not separately priced in disclosures.

Pipeline / development-stage offerings

OfferingStatusVehicleSource
Own-brand autonomous mobile robot (AMR) solutions for healthcareIn development; positioned to relieve Hong Kong healthcare manpower shortage; residual IPO proceeds (HK$0.4 million) fully used in FY2025Techmetics Sonne Limited (60% subsidiary since Feb 2025)FY2025 results
Own-brand medical devicesSubsidiary established to facilitate future developmentUnnamed subsidiaryFY2025 and FY2026 results MD&A
Healthcare automation solutionsTwo software engineers recruited; research into medical and healthcare automationGroup R&DFY2024 results (business progress)
E-commerce platformWebsite redesigned with online store for retail customersGroupFY2024 results
ShowroomNew showroom with device samples for customer inspection prior to orderingHQFY2024 results

Financial Narrative

All figures HK$'000 unless stated; FY ends 31 March. Sources: FY2023 AR (FY2022–FY2023); FY2024, FY2025 and FY2026 audited results announcements.

Income statement: notes and sources

Notes: (1) FY2023 "other gains or losses" was reported as HK$417,000 in the FY2023 AR; the FY2024 announcement re-presented it as HK$338,000 with the HK$79,000 receivable-allowance reversal shown separately — the totals reconcile. (2) In FY2022 the HK$87,000 receivable allowance was not presented as a separate line in the FY2023 AR income statement. (3) Dividends are declared after year end as "interim dividends in lieu of a final dividend".

Analyst-derived profitability measures

Definitions: Core operating profit = gross profit − distribution & selling − administrative expenses (excludes other income, investment gains/losses, associates and the bargain purchase gain). EBITDA = profit before tax + finance costs + depreciation of PP&E and right-of-use assets (reported basis; includes other income such as interest and grants). D&A from the "profit before tax" notes.

Revenue CAGR: FY2022–FY2026 four-year CAGR ≈ 8.8%; FY2019–FY2026 seven-year CAGR ≈ 8.2% (analyst-derived from reported revenue).

Commentary — revenue and margins. Revenue has compounded at a steady high-single-digit rate with one step-change (FY2025, +15.3%) driven by hospital equipment tenders. Gross margin peaked at 51.5% in FY2023 (management cited improved transport cost control) and has since contracted 540 basis points to 46.1% as lower-margin equipment grew. The gross profit line consequently grew only 1.4% in FY2026 despite 6.6% revenue growth.

Commentary — operating leverage. Administrative expenses rose 16.0% in FY2024 (marketing activity and salary increases) and 6.9% in FY2025 (salaries), then were flat in FY2026 (HK$37.9 million). Flat opex in FY2026 is the main reason core operating margin held at 7.0%. Staff costs rose from HK$18.2 million (FY2022) to HK$24.5 million (FY2026).

Commentary — quality of earnings. Reported profit has been meaningfully supported by non-operating items: other income (interest plus government R&D and employment subsidies) contributed HK$4.2 million in FY2024 and HK$3.4 million in FY2025, versus HK$1.7 million in FY2026. The FY2025 profit also included a HK$975,000 bargain purchase gain, partly offset by a HK$1.529 million write-down of the Techmetics investment. Management attributed the FY2026 decline in profit (HK$9.2 million to HK$8.1 million) mainly to lower government grants. Bank interest income fell from HK$1.615 million to HK$940,000 in FY2026 as cash balances declined and rates eased. The FY2024 effective tax rate of 5.1% was attributed to tax planning adopted by group companies (FY2024 MD&A); unutilised tax losses of HK$7.1 million existed at 31 March 2023.

Balance sheet

Notes: Negative net debt = net cash. No goodwill is recognised on the balance sheet; goodwill of HK$663,000 arising on the 寶存 investment is embedded in the associate carrying amount (FY2023 AR Note 16). No intangible assets other than the club membership are recognised.

Commentary — balance sheet. The group has carried no bank debt since listing; the only financial liabilities are short warehouse/office leases. Equity has grown every year, and equity represented 87% of total assets at FY2026. The critical change is the composition of current assets: net trade receivables tripled from HK$13.9 million (FY2024) to HK$42.6 million (FY2026), while cash fell HK$7.1 million in FY2026. The FY2026 receivables ageing shows HK$29.533 million over 90 days (FY2025: HK$593,000) against stated credit terms of 0–30 days — consistent with slow-paying tender/project customers, but this has not been explained in the results announcement. Loss allowance was raised only modestly (HK$1.733 million vs HK$1.461 million).

Cash flow

Sources: FY2023 AR consolidated cash flow statement (FY2022–FY2023). FY2024–FY2026 operating cash flow, capex and lease repayments were not captured in the sources reviewed (the results announcements omit the cash-flow statement; the full annual reports contain them). Dividends paid FY2024–FY2026 from dividend notes; net change in cash derived from balance sheets; buybacks confirmed nil by "purchase, sale or redemption" disclosures.

Commentary — cash generation. Cash conversion is volatile and dominated by working-capital swings. FY2022 operating cash flow was negative (receivables build of HK$9.7 million); FY2023 was strongly positive. The FY2026 combination of rising profit-before-tax-ex-items, a HK$17.2 million increase in net trade receivables and a HK$7.1 million cash decline (after only HK$2.0 million of dividends) strongly suggests that FY2026 operating cash flow was weak, but the exact figure is not reported in the announcement and is not estimated here.

Ratios (analyst-derived)

Methodology: ROE = attributable profit / average attributable equity; ROA = total profit / average total assets; ROIC = core operating profit × (1 − 16.5%) / year-end invested capital (total equity + lease liabilities − cash); interest coverage = core operating profit / lease interest; CCC on year-end balances (DSO = net trade receivables / revenue × 365; DIO = inventory / cost of revenue × 365; DPO = trade payables / cost of revenue × 365). FY2021 year-end balances (equity HK$93.052 million; total assets HK$112.010 million) used for FY2022 averages.

Commentary — returns. ROE of 7–9% is modest and structurally depressed by the large cash pile (cash was 45% of equity at FY2026). ROIC on operating capital is higher but has declined from 15.6% (FY2023) to 8.8% (FY2026) as receivables swelled invested capital from HK$42 million to HK$66 million. The cash conversion cycle lengthened to 286 days in FY2026 — the inventory side improved, but DSO more than doubled from FY2024. Dividend payout has been cut from 42–59% (FY2022–FY2023) to 21–25% (FY2024–FY2026) despite higher earnings, with DPS fixed at HK$0.25 cents for three consecutive years.

Half-year trend (analyst-derived from interim headline)

Derivation: 1H FY2026 revenue approx. HK$52.5 million (+25.9%, per the 21 November 2025 interim announcement headline) implies 1H FY2025 ≈ HK$41.7 million; second halves = full-year less first half. The derived 2H FY2026 revenue was about 8.5% below 2H FY2025, indicating that growth was front-loaded and decelerated sharply in the second half. Interim profit was approx. HK$3.9 million, implying roughly HK$4.2 million in 2H FY2026.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

Category (HKD K)FY2022FY2023FY2024FY2025FY2026

Medical consumables (HKD K)

53,69955,06154,98558,64661,902

Medical equipment (HKD K)

14,25117,47622,89931,65734,248

Medical instruments (HKD K)

2,4451,8071,7561,6721,540

Maintenance services (HKD K)

1,3942,2012,1072,3172,867

Rental income (HKD K)

189156156156156

Total revenue (HKD K)

71,97876,70181,90394,448100,713

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Category growth (%)

Category growth (%)FY2023FY2024FY2025FY2026

Medical consumables growth (%)

2.5-0.16.75.6

Medical equipment growth (%)

22.631.038.28.2

Medical instruments growth (%)

-26.1-2.8-4.8-7.9

Maintenance services growth (%)

57.9-4.310.023.7

Total revenue growth (%)

6.66.815.36.6

Category share (%)

Category share (%)FY2022FY2023FY2024FY2025FY2026

Medical consumables share (%)

74.671.867.162.161.5

Medical equipment share (%)

19.822.828.033.534.0

Medical instruments share (%)

3.42.42.11.81.5

Maintenance services share (%)

1.92.92.62.52.8

Rental income share (%)

0.30.20.20.20.2

Revenue by Segment by Recognition Timing

Recognition timing (HKD K)FY2022FY2023FY2024FY2025FY2026

Recognised over time (HKD K)

1,3942,2012,1072,3172,867

Recognised at a point in time (HKD K)

70,39574,34479,64091,97597,690

Group Entities

EntityPlace of incorporationEffective interestPrincipal activitySource

Grand Brilliance Group Holdings Limited

Cayman Islands

Listed parent

Investment holding

FY2026 results

A&A Brilliance Limited

BVI (4 Jul 2017)

100% direct

Investment holding

FY2023 AR Note 32

鴻日醫療有限公司

Hong Kong (15 Oct 1997)

100% indirect

Medical device sourcing and after-sales services

FY2023 AR Note 32

向日國際有限公司

Hong Kong (11 Mar 2009)

100% indirect

Medical device sourcing and healthcare product development

FY2023 AR Note 32

向日科技國際有限公司

Hong Kong (4 Jul 2016)

100% indirect

Trademark holding

FY2023 AR Note 32

Sonne (UK) Limited

United Kingdom (26 Aug 2016)

100% indirect

Trademark holding

FY2023 AR Note 32

Solar Service Engineering Holdings Limited

BVI (12 Mar 2019)

100% indirect

Investment holding

FY2023 AR Note 32

鴻日工程服務有限公司

Hong Kong (10 May 2019)

100% indirect

Maintenance services

FY2023 AR Note 32

Macau subsidiary (name not captured)

Macau (FY2024)

Non-wholly owned (stake not disclosed in sources reviewed)

Expansion of Macau business; subject to 12% Macau complementary tax

FY2024 results MD&A; FY2025/FY2026 tax note

Techmetics Sonne Limited (晉暉科技有限公司)

Hong Kong (19 Aug 2021)

60% indirect since 6 Feb 2025 (previously 20% associate)

Healthcare AMR solutions, OEM sourcing, R&D

FY2025 results Note 16

Own-brand medical device subsidiary (name not captured)

Hong Kong (assumed; not stated)

—

Development of own-brand medical devices

FY2025/FY2026 results MD&A

寶存有限公司

Hong Kong (1 Aug 2016)

16.1% associate (as at 31 Mar 2023)

Supply chain solutions

FY2023 AR Note 16

“—” = not publicly disclosed.

Income Statement and Per-Share Data

Metric (HKD K)FY2022FY2023FY2024FY2025FY2026

Revenue (HKD K)

71,97876,70181,90394,448100,713

Cost of revenue (HKD K)

-35,631-37,189-39,962-48,726-54,331

Gross profit (HKD K)

36,34739,51241,94145,72246,382

Other income (HKD K)

261,4754,2393,4211,722

Other gains or losses (HKD K)

-326338-910-648703

Bargain purchase gain (HKD K)

0009750

Distribution and selling expenses (HKD K)

-1,197-1,209-1,319-1,397-1,454

Administrative and other operating expenses (HKD K)

-29,232-30,470-35,354-37,785-37,896

Trade receivable loss allowance (provision)/reversal (HKD K)

079-1810-272

Share of associates' results (HKD K)

0-196-2631874

Finance costs — lease interest (HKD K)

-140-152-106-208-214

Profit before tax (HKD K)

5,4789,3778,21010,1089,045

Income tax (HKD K)

-1,430-1,815-420-917-937

Profit for the year (HKD K)

4,0487,5627,7909,1918,108

Profit attributable to owners (HKD K)

4,0487,5627,8559,4608,413

Non-controlling interests (HKD K)

00-65-269-305

Basic and diluted EPS (HK cents)

0.510.950.981.181.05

Dividend per share declared for the year (HK cents)

0.30.40.250.250.25

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Core operating profit (HKD K)

5,9187,8335,2686,5407,032

Depreciation — PP&E (HKD K)

615389617746679

Depreciation — right-of-use assets (HKD K)

3,6373,9773,9992,8891,905

EBITDA (HKD K)

9,87013,89512,93213,95111,843

Gross margin (%)

50.551.551.248.446.1

Core operating margin (%)

8.210.26.46.97.0

EBITDA margin (%)

13.718.115.814.811.8

Pre-tax margin (%)

7.612.210.010.79.0

Net margin (%)

5.69.99.59.78.1

Effective tax rate (%)

26.119.45.19.110.4

Admin expenses as % of revenue (%)

40.639.743.240.037.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet

Metric (HKD K)FY2022FY2023FY2024FY2025FY2026

Total assets (HKD K)

110,324115,248114,495132,192134,702

Non-current assets (HKD K)

12,90213,60710,30010,5527,736

Current assets (HKD K)

97,422101,641104,195121,640126,966

Cash and cash equivalents (HKD K)

55,33661,08559,98860,23553,123

Inventories (HKD K)

22,44222,15324,50027,79925,973

Trade receivables, net (HKD K)

17,31015,70313,94325,31742,552

Trade and other receivables, deposits and prepayments — current (HKD K)

19,13217,63018,20331,61546,797

Bank borrowings (HKD K)

00000

Lease liabilities — current (HKD K)

2,4003,7661,4291,8521,624

Lease liabilities — non-current (HKD K)

2,08168802,054429

Total lease liabilities (HKD K)

4,4814,4541,4293,9062,053

Net debt including leases (HKD K)

-50,855-56,631-58,559-56,329-51,070

Trade payables (HKD K)

7,1075,9693,8757,9256,291

Current liabilities (HKD K)

14,73415,88911,21918,69516,722

Total liabilities (HKD K)

16,81516,57711,21920,74917,151

Equity attributable to owners (HKD K)

93,50998,671103,326110,786117,199

Total equity (HKD K)

93,50998,671103,276111,443117,551

Other assets — club membership, indefinite life (HKD K)

2,6902,6902,6902,6902,680

Working capital (current assets less current liabilities) (HKD K)

82,68885,75292,976102,945110,244

Cash Flow

Metric (HKD K)FY2022FY2023FY2024FY2025FY2026

Operating cash flow (HKD K)

-3,33412,658———

Capital expenditure — PP&E purchases (HKD K)

-784-63———

Free cash flow (OCF less capex) (HKD K)

-4,11812,595———

Lease principal repaid (HKD K)

-3,842-3,847———

Dividends paid (HKD K)

-3,600-2,400-3,200-2,000-2,000

Share buybacks (HKD K)

00000

Net change in cash and equivalents (HKD K)

-14,8765,749-1,097247-7,112

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE (%)

4.37.97.88.87.4

ROA (%)

3.66.76.87.56.1

ROIC (%)

11.615.69.89.98.8

Current ratio (x)

6.616.409.296.517.59

Bank debt to equity (x)

00000

Lease liabilities to equity (%)

4.84.51.43.51.7

Net debt to EBITDA (x)

-5.15-4.08-4.53-4.04-4.31

Interest coverage (x)

42.351.549.731.432.9

Asset turnover (x)

0.650.680.710.770.75

Days sales outstanding (days)

87.874.762.197.8154.2

Days inventory outstanding (days)

229.9217.4223.8208.2174.5

Days payables outstanding (days)

72.858.635.459.442.3

Cash conversion cycle (days)

244.9233.5250.5246.6286.4

Dividend payout on declared DPS (%)

59.342.325.521.123.8

Income Statement

Period metric1H FY20252H FY20251H FY20262H FY2026

Revenue (HKD Mn)

41.752.752.548.2

Region revenue (HKD K)

Region revenue (HKD K)FY2022FY2023FY2024FY2025FY2026

Hong Kong and other (as reported, total) (HKD K)

71,97876,70181,90394,448100,713

Geographic Revenue

Supplier country (number of suppliers)FY2022FY2023

Mainland China (suppliers)

1922

United States (suppliers)

1515

Germany (suppliers)

55

France (suppliers)

44

Malaysia (suppliers)

33

Hong Kong (suppliers)

03

Singapore (suppliers)

01

Total suppliers (suppliers)

4653

Valuation Metric Details

Valuation metricValueBasis

Share price

HK$0.169

etnet last price

Shares outstanding

800,000,000

FY2026 results

Market capitalisation

HK$135.2m

Calculated

Enterprise value

HK$84.5m

Market cap − cash HK$53.1m + leases HK$2.1m + NCI HK$0.35m

Trailing P/E

16.1x

FY2026 EPS 1.05 cents

EV/EBITDA

7.1x

FY2026 EBITDA HK$11.8m (analyst-derived)

EV/Sales

0.84x

FY2026 revenue

P/B

1.15x

Equity attributable HK$117.2m

Dividend yield

1.5%

DPS 0.25 cents

Net cash as % of market cap

38%—

Dividend metric

Dividend metricFY2022FY2023FY2024FY2025FY2026

DPS declared for the year (HK cents)

0.30.40.250.250.25

Total dividend declared for the year (HKD K)

2,4003,200200020002000

Dividends paid in the year (HKD K)

3,6002,4003,20020002000

Analyst Conclusions

Management guidance

No quantitative guidance. Management states continued optimism on Hong Kong healthcare given population ageing, health awareness and automation demand, and that it is seeking investment opportunities to diversify (FY2026 MD&A).

Consensus

No consensus estimates exist.

Bull case

  1. Structural tender pipeline: equipment revenue more than doubled from HK$14.3m (FY2022) to HK$34.2m (FY2026) on hospital expansion tenders; if public capital works continue, the installed base also lifts recurring maintenance (+23.7% in FY2026) and consumables pull-through.

  2. Deep value with optionality: at ~7x EV/EBITDA and with net cash equal to ~38% of market cap, the market ascribes modest value to a consistently profitable business, before any own-brand or AMR upside.

  3. Capital-return catalyst: a payout ratio of only ~24% and a fresh repurchase mandate give scope for higher dividends or buybacks from HK$53m of idle cash.

Bear case

  1. Receivables quality: HK$29.5m over 90 days (69% of net trade receivables) against 0–30-day terms; an impairment of even one-third would erase more than a year's profit.

  2. Decelerating growth and margin compression: derived 2H FY2026 revenue fell ~8.5% YoY; gross margin has fallen four years running; grant and interest income are fading.

  3. Governance and capital-allocation risk: controlling-shareholder dominance (combined roles, spouse on audit committee, related-party lease and JV co-investment), recurrent INED departures, and a track record of small, value-destructive technology investments.

Key catalysts and monitorables (next 12 months)

1H FY2027 interim results: (six months to 30 Sep 2026; expected around November 2026): watch revenue against the strong 1H FY2026 comparative (~HK$52.5m), gross margin, and especially collection of the >90-day receivables.

FY2026 Annual Report cash-flow statement: (published 21 Jul 2026): confirm operating cash flow and capex.

Board composition: explain the three Company Information Sheet updates (31 Aug, 8 Sep, 18 Sep 2026).

Hospital Development Plan tender awards: and HKSAR budget signals on hospital capital works.

Any first revenue: from Techmetics Sonne / own-brand AMR or devices; Macau revenue disclosure.

Use of repurchase mandate: or any change in dividend level.

M&A: given repeated statements about seeking investment opportunities.

Analyst verdict

Grand Brilliance Group is a small, durable, conservatively financed Hong Kong distribution business that has executed better on the top line than its GEM-micro-cap status might suggest: revenue has compounded at close to 9% a year since FY2022 to cross HK$100 million in FY2026, it has never needed bank debt, and it has paid a dividend every year. The engine of that growth, however, has changed character. Public-hospital equipment tenders now represent a third of sales, bringing lower gross margins, lumpier timing and — on the evidence of the FY2026 balance sheet — much slower cash collection.

Against this, valuation is undemanding. Roughly 38% of the market capitalisation is covered by net cash, the stock trades near 1.15x book and about 7x EV/EBITDA, and the payout ratio leaves ample room for higher distributions. Yet capital-allocation discipline has been mixed: the AMR diversification has so far yielded write-downs offset by an accounting gain, related-party features recur, and governance relies heavily on a single founder who holds both leadership roles and 71% of the shares.

On balance, the investment case is neutral with a cautious bias until the receivables position is resolved. Confirmation that the overdue balances were collected after year end — ideally visible in the 1H FY2027 interim results — together with stabilisation of gross margin near 46% and a more generous use of surplus cash would move the assessment towards positive. Conversely, an impairment charge, further INED turnover or another non-core investment would reinforce the bear case. Liquidity constraints typical of GEM stocks argue for position sizing appropriate to a micro-cap.


Prepared from public HKEX filings and identified aggregators as of 10 October 2026.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedAge (as stated in FY2023 AR, June 2023)Background and educationSource

Ms. Wong Bik Kwan Bikie (黃碧君)

Chairman, CEO, executive director, compliance officer; remuneration committee member

Director 5 Jul 2017; ED 18 Sep 2017; Chair & CEO 1 Mar 2018

54

Founded the group in Nov 1997; over 29 years in Hong Kong medical device market (as of 2023); Diploma in General Nursing (1990), MBA, University of South Australia (1999); awards incl. Greater Bay Area Outstanding Women Entrepreneur Award (2018); vice-chair of Yan Oi Tong and of a GBA Hong Kong women entrepreneurs association

FY2023 AR

Dr. Miu Yin Shun Andrew (苗延舜)

Non-executive director; audit committee member

18 Sep 2017

56

MBChB, Chinese University of Hong Kong (1990); FRCS Edinburgh (1995), orthopaedics fellowships; MSc Sports Medicine & Health Science, CUHK (2015); orthopaedic specialist since 2011; spouse of Ms. Wong; advises on medical device technical information

FY2023 AR

Mr. Chiu Man Wai (趙文煒)

Non-executive director; nomination committee member

18 Sep 2017

54

BA Mathematics (1990) and MSc Mathematical Modelling & Numerical Analysis (1991), University of Oxford; research roles incl. head of research at BNP Paribas Equities Hong Kong (1996–2004); director of financial investment and insurance advisory companies; advises on investor relations

FY2023 AR

Mr. Ng Leung Sing SBS, JP (吳亮星)

INED; nomination committee chair

1 Mar 2018

73

Director, BOC-Group Trustee (HK) since 2009; former director of HK Mortgage Corporation (2014–2018); INED of SmarTone (315) and Nine Dragons Paper (2689); former HK deputy to National People's Congress; former Legislative Council member; law diploma, University of East Asia, Macau (1987)

FY2023 AR

Mr. Chow Ming Po Aaron (周明寶)

INED; remuneration committee chair; audit and nomination committee member

21 Jun 2021

50

Practising solicitor; LLB and PCLL, University of Hong Kong (1995/1996); co-founder and partner of a Hong Kong law firm since 2006

FY2023 AR

Mr. 趙㠶華 (English name not captured)

INED; audit committee chair; remuneration committee member

1 Jun 2025

Not captured

Appointed to restore accounting-expertise INED requirement under GEM Rule 5.05(2); biography not captured in sources reviewed

FY2025 and FY2026 results

Executive Leadership Team

NameTitleJoinedAge (June 2023)Background

何海燕

General Manager

Mar 2020 (GM from 2021)

42

Bachelor of Commerce (Marketing & Advertising), Curtin University; product manager at Synapse Therapeutics (2011–2018)

張創智

Financial Controller

12 Aug 2019

45

BBA, CUHK (1999); FCPA (HKICPA), FCCA; oversees accounting, finance, company secretarial and internal control

李春成

Business Development Manager

Jan 1998

53

Over 23 years in medical equipment; former electrical engineer

劉偉民

Marketing, Projects & Service Engineering Manager

Feb 2015

36

BEng Medical Engineering, HKU (2008); MSc Biomedical Engineering, CUHK (2009)

李嘉文

Company Secretary (external provider)

——

Member of HKCGI and CGI; over 17 years' company secretarial experience

Directors' Remuneration

DirectorFeesSalaries & benefitsDiscretionary bonusPensionTotal

Ms. Wong Bik Kwan Bikie

02,9921,211224,225

Dr. Miu Yin Shun Andrew

120000120

Mr. Chiu Man Wai

120000120

Mr. Ng Leung Sing

120000120

Mr. Wong Lung Wo James (former)

120000120

Mr. Chow Ming Po Aaron

120000120

Total

6002,9921,211224,825

Board & Management Changes

DateChangeContext

17 Sep 2021

Chan Ping Keung retired as INED

Did not seek re-election, citing work adjustment

21 Jun 2021

Chow Ming Po Aaron appointed INED

—

18 Sep 2023

Wong Lung Wo James resigned; Mui Wai Sum appointed INED and audit chair

—

14 Mar 2025

Mui Wai Sum resigned (other commitments)

Triggered non-compliance with GEM Rules 5.05(1), 5.05(2), 5.28 and 5.34

1 Jun 2025

趙㠶華 appointed INED, audit chair

Compliance restored

Aug–Sep 2026

Company Information Sheets (Form G) updated 31 Aug, 8 Sep and 18 Sep 2026

may reflect post-AGM or administrative changes — monitor

Major Shareholders

HolderSharesStake (%)NatureSource / date

B&A Success Limited (wholly owned by Ms. Wong)

568,028,00171.0

Beneficial owner

FY2023 AR (31 Mar 2023)

Ms. Wong — share options

7,980,000 underlying

1.0

Options at HK$0.12, expiring 17 Apr 2024 (post-expiry status not captured)

FY2023 AR

Mr. Chiu Man Wai (via Infinite Crystal Limited)

9,620,0001.20

Controlled corporation

FY2023 AR

Mr. Chow Ming Po Aaron

7,810,0000.98

Beneficial owner

FY2023 AR

Public / other

~214.5 million

~26.8

—

Analyst-derived

Competitive Landscape

Key Competitors

#CompetitorTypeOverlap with GBG
1

Medtronic (Hong Kong subsidiary)

Multinational direct sales

Hospital equipment and consumables tenders

2

Johnson & Johnson MedTech

Multinational direct sales

Surgical consumables and instruments

3

B. Braun

Multinational direct sales

Consumables, infusion, instruments

4

BD (Becton, Dickinson)

Multinational direct sales

Consumables

5

Siemens Healthineers

Multinational direct sales

Capital equipment

6

GE HealthCare

Multinational direct sales

Capital equipment

7

Philips

Multinational direct sales

Capital equipment, monitoring

8

Olympus

Multinational direct sales

Endoscopy equipment and instruments

9

DKSH

Regional market-expansion distributor

Third-party distribution of healthcare products

10

Zuellig Pharma

Regional healthcare distributor

Healthcare distribution logistics

11

Private Hong Kong distributors (numerous; unnamed)

Local SMEs

Agency-based distribution of niche brands

Competitor Detail

Metric (latest FY)Grand Brilliance (FY2026)

Revenue

HK$100.7m

Revenue growth

6.6%

Gross margin

46.1%

Operating margin (core)

7.0%

R&D intensity

4.6%

Company Snapshot

$12.9M

Revenue

51

Employees

1997

Founded

Grand Cayman, Cayman Islands

Headquarters

SWOT Analysis

Strengths

  • Debt-free balance sheet: zero bank borrowings at every year end FY2022–FY2026; net cash HK$51.1 million at FY2026 (FY2026 results).
  • Consistent profitability: profitable every year since at least FY2019; attributable profit HK$8.4 million in FY2026.
  • High gross margin for a distributor: 46–52% over five years.
  • Tender track record: First Hospital Development Plan equipment wins drove revenue +15.3% (FY2025) and +6.6% (FY2026).
  • Service capability: dedicated maintenance subsidiary; maintenance revenue doubled from HK$1.39m (FY2022) to HK$2.87m (FY2026).
  • Founder alignment: Chairman/CEO controls 71% via B&A Success; non-compete deed in place since 1 March 2018.
  • Government R&D support access: HK$2.4m of ITF-related grants in FY2024.

Weaknesses

  • Receivables deterioration: HK$29.5 million over 90 days at FY2026 vs HK$0.6 million at FY2025; DSO 154 days vs 0–30-day credit terms.
  • Inventory-heavy model: DIO of 175–230 days; inventory HK$26.0 million (FY2026).
  • Margin erosion: gross margin down from 51.5% (FY2023) to 46.1% (FY2026).
  • High fixed costs: admin expenses 37.6% of revenue (FY2026).
  • Earnings reliance on non-operating income: other income equal to 34% of profit before tax in FY2025 (HK$3.4m of HK$10.1m).
  • Governance concentration: combined Chair/CEO, spouse on board and audit committee, no internal audit department, recurrent INED turnover.
  • Failed technology investment: Techmetics stake written off (HK$1.95m cumulative FV losses FY2024–FY2025).

Opportunities

  • Continued hospital development spending (First and Second Hospital Development Plans).
  • Macau market entry (subsidiary since FY2024).
  • Own-brand devices could lift margins versus pure distribution.
  • Healthcare automation demand driven by manpower shortages.
  • Recurring service revenue from a growing installed equipment base.
  • Capital deployment: HK$53m cash and 2026 repurchase/treasury-share mandate could support buybacks, higher dividends or acquisitions.

Threats

  • Customer concentration: Customer A 15.6% and Customer B 10.3% of FY2026 revenue.
  • Supplier concentration: top five suppliers 73.2% of FY2023 purchases.
  • Public budget constraints could delay tenders.
  • Multinational disintermediation of distributor agencies.
  • Geopolitical and trade frictions affecting US and Mainland China supply.
  • Credit losses if overdue receivables prove impaired; allowance only HK$1.73m vs HK$29.5m >90 days.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
14 Mar 2025 (context)INED Mui Wai Sum resigns; non-compliance with GEM board/committee rules FY2025 resultsGovernance gap (pre-window context)
27 May 2025Announcement on INED appointment Referenced in FY2025 resultsRemedies non-compliance
30 May 2025Board meeting notice for FY2025 results HKEXRoutine
1 Jun 2025趙㠶華 appointed INED and audit committee chair FY2025 resultsGEM compliance restored
20 Jun 2025FY2025 results: revenue HK$94.4m (+15.3%), attributable profit HK$9.46m (+20.4%), EPS 1.18 centsRecord revenue and profit; First Hospital Development Plan tenders
20 Jun 2025Interim dividend HK$0.25 cents in lieu of final declared FY2025 resultsFlat DPS
20 Jun 2025Disclosure of Techmetics liquidation and Techmetics Sonne step acquisition FY2025 resultsStrategic AMR reset
18 Jul 2025FY2025 annual report filed; dividend record date Webb-site; FY2025 resultsRoutine
11 Aug 2025FY2025 dividend paid FY2025 resultsHK$2.0m outflow
5 Sep 2025AGM FY2025 resultsRoutine
3 Nov 2025Monthly return for October 2025 HKEXRoutine; no change in share capital
11 Nov 2025Board meeting notice for interim results HKEXRoutine
21 Nov 20251H FY2026 interim results: revenue approx. HK$52.5m (+25.9%); profit approx. HK$3.9m HKEX (etnet headline)Strong first half
27 Nov 20252025 Interim Report published HKEXRoutine
1 Dec 2025 – 4 May 2026Monthly returns (Nov 2025 to Apr 2026) HKEXNo changes in issued shares
27 May 2026Board meeting notice for FY2026 results HKEXRoutine
26 Jun 2026FY2026 results: revenue HK$100.7m (+6.6%), attributable profit HK$8.41m (−11.1%), EPS 1.05 cents; gross margin 46.1%First year above HK$100m revenue; profit down on lower grants
26 Jun 2026Trade receivables over 90 days disclosed at HK$29.5m (FY2025: HK$0.6m) FY2026 results Note 12Key credit/working-capital red flag
26 Jun 2026Interim dividend HK$0.25 cents in lieu of final (ex-date 13 Jul, record 17 Jul, paid 10 Aug 2026) FY2026 results; dividend announcementThird consecutive flat DPS
2 Jul 2026Monthly return for June 2026 HKEXRoutine
21 Jul 20262026 Annual Report published HKEXFull cash-flow and remuneration disclosure available
21 Jul 2026Circular: general mandates (issue, treasury shares, repurchase), director re-election, re-appointment of BDO; AGM notice HKEXCapital-management flexibility
3 Aug 2026 / 1 Sep 2026Monthly returns for July and August 2026 HKEXRoutine
10 Aug 2026FY2026 dividend paid Dividend announcementHK$2.0m outflow
31 Aug 2026Company Information Sheet (Form G) updated HKEX–
8 Sep 2026Company Information Sheet updated HKEX–
11 Sep 2026AGM held; poll results announced HKEX–
18 Sep 2026Company Information Sheet updated HKEXThree updates in three weeks — possible board/officer change; monitor
2 Oct 2026Monthly return for September 2026 HKEXRoutine

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Revenue rose from HKD 72 Mn in FY2022 to HKD 100.7 Mn in FY2026.
Grand Brilliance Group Holdings Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue7276.781.994.4100.7
Cost of revenue-35.6-37.2-40-48.7-54.3
Gross profit36.339.541.945.746.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.